MSKCC in the News: January 24 – February 13

  • IBM Corp., the health insurer WellPoint Inc. and MSKCC announced two Watson-based applications – one to help diagnose and treat lung cancer and one to help manage health insurance decisions and claims.
  • A press release announced that researchers at MSKCC have treated the first patient with a new experimental vaccinia virus-based cancer therapy designed for patients with malignant pleural mesothelioma or non-small cell lung cancer.
  • Peter Bach of MSKCC is quoted in a Nature News article about the impact of the economic downturn on US academic medical campuses like the University of California, San Francisco (UCSF).

MSKCC in the News: December 26 – January 9

  • Lorus Therapeutics Inc. announced that its Phase I clinical study, conducted at MSKCC and the MD Anderson Cancer Center, of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
  • MSKCC’s Dr. Peter Bach was quoted in a Reuters article about a study that found that pediatricians-in-training are more likely to plan to go into primary care – rather than a specialty field – if they have lots of debt from college and medical school.
  • MSKCC was featured in Health Magazine’s top 12 medical breakthroughs of 2012.